Neurogene Inc.
General ticker "NGNE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $492.9M (TTM average)
Neurogene Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 2.7%: low 33.93$, high 35.84$
Factors to consider:
- Total employees count: 131 (+22.4%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Clinical trial failure, No approved products, Capital raising, Construction delays, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [12.96$, 33.03$]
- 2026-12-31 to 2027-12-31 estimated range: [9.88$, 26.35$]
Financial Metrics affecting the NGNE estimates:
- Negative: with PPE of -4.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 91.78 > 81.92
- Negative: negative Net income
Short-term NGNE quotes
Long-term NGNE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.93MM | $0.00MM |
| Operating Expenses | $55.58MM | $83.53MM | $103.33MM |
| Operating Income | $-55.58MM | $-82.61MM | $-103.33MM |
| Non-Operating Income | $19.27MM | $7.46MM | $12.98MM |
| Interest Expense | $0.01MM | $0.01MM | $0.01MM |
| R&D Expense | $44.39MM | $60.92MM | $75.01MM |
| Income(Loss) | $-36.32MM | $-75.14MM | $-90.35MM |
| Net Income(Loss)* | $-36.32MM | $-75.14MM | $-90.35MM |
| Stockholders Equity | $186.02MM | $310.38MM | $264.89MM |
| Assets | $222.57MM | $335.73MM | $288.60MM |
| Operating Cash Flow | $-51.42MM | $-70.60MM | $-77.17MM |
| Capital expenditure | $0.32MM | $0.81MM | $1.18MM |
| Investing Cash Flow | $25.64MM | $-125.26MM | $14.00MM |
| Financing Cash Flow | $92.48MM | $184.07MM | $30.43MM |
| Earnings Per Share** | $-2.83 | $-4.28 | $-4.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.